TROPONIN ESSENTIAL GUIDELINES: A PRACTICAL IMPLEMENTATION GUIDE

 
PRESENTER
RECORDING SLIDES

TROPONIN ESSENTIAL GUIDELINES: A PRACTICAL IMPLEMENTATION GUIDE

PRESENTER

Ruth Cantu, BSN, RN, AACC
Accreditation Product Development
ACC Accreditation Services


SUMMARY

This presentation will address the updates for Myocardial Infarction Guidelines which are important for clinicians and laboratorians as they provide valuable information on the new recommendations for serial Troponins as well as assay specifications. Information regarding Acute Coronary Syndromes (ACS) will provide a summary of statistics along with definitions of indicators under ACS. The methods for treating Myocardial Infarction (MI), also known as Acute MI or heart attack, including the acute phase in the ED as well as the diagnostic expectations for patients in observation status requiring accelerated serial marker protocols will also be discussed.

The presentation will include a brief over-view of the high-sensitive Troponin and discussion on Troponin Turn-Around-Time (TAT), testing methodologies and a review of quality practices to optimize patient care.
Learning objectives
  1. Review updates to the Myocardial Infarction (MI) Definition and other relevant guidelines
  2. Identify guideline-driven best practice recommendations on the use of biomarkers in the treatment of Acute Coronary Syndrome (ACS)
  3. Discuss Troponin turn-around-time (TTAT) and guideline recommendations for assay use in clinical practice
  4. Describe quality practices that optimize the care and outcomes of ACS patients

Continuing Education:
- One P.A.C.E.
® contact hour will be provided for this basic level session until August 21, 2019. Abbott is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program.

- This session is approved for one Florida CE credit. Florida Board of Clinical Laboratory Personnel approved number: 50-12563

- This program has been approved by the American Association of Critical-Care Nurses (AACN) for 1.00 CERPs, Synergy CERP Category A, File number 22490

After viewing the recording, watch for the evaluation to appear in your browser. A link to your certificate will be emailed within two weeks of receipt of your completed evaluation.

PROCESS REDESIGN IN AMBULATORY EMERGENCY CARE
UTILISING POINT OF CARE TESTING

 
PRESENTER
RECORDING SLIDES

PROCESS REDESIGN IN AMBULATORY EMERGENCY CARE UTILISING
POINT OF CARE TESTING


PRESENTER


Phil Weihser BSc. PGCert. MSc.
James Paget University Hospital NHS Trust, UK

SUMMARY

Emergency departments in many countries are suffering from overcrowding and increased admission rates. This is due to numerous factors such as a rise in chronic disease, an ageing population and access to care.

Many healthcare systems are looking at models of care to help reduce the burden on acute services by decreasing the length of stay in hospital, and by reducing the number of unnecessary admissions.

This webinar highlights how a university hospital in the UK has tackled the problem, by implementing a 7-day Ambulatory Emergency Care service (AEC). The speaker will highlight the clinical, financial and operational benefits achieved through the novel use of point of care testing, evidence-based service redesign, condition specific pathways, and access to senior clinical  decision makers.
Learning objectives
  1. Discuss how to redesign service in acute and emergency medicine
  2. Demonstrate how point-of-care testing pathways can help drive new models of care
  3. Examine the potential improvement metrics including reduction in hospital admissions and length of stay



This event is produced by Whitehat Communications and sponsored by Abbott Point of Care.

Certificate of attendance:
You can receive a certificate of attendance for viewing the recording until January 12, 2019. After viewing the recording, watch for the evaluation to appear in your browser. A link to your certificate will be emailed within two weeks of receipt of your completed evaluation.
   
 

ACT TESTING

   
PRESENTER
RECORDING SLIDES

ACT TESTING:
WHEN THERE'S NO ROOM FOR DOUBT


PRESENTER


Dr. Florian Falter, MD
Royal Papworth Hospital, UK

SUMMARY

ACT tests with some traditional analysers can lead to highly variable results, raising doubt about the accuracy of critical results1. Additionally, some second generation systems have diverged from using the traditional standard Celite and Kaolin activator biochemistry.

In this educational webinar, Dr.Falter will introduce different ACT technologies and discuss best use of modern ACT testing technology. He will also discuss the clinical impact that different ACT analysis methods can have, along with key laboratory aspects of coagulation testing during cardiac surgery.

 1 Reference: Ojito JW et al. J Extra Corpor Technol 2012;44:15-20
Learning objectives
  1. Examine laboratory requirements of test accuracy and reliability
  2. Differentiate between laboratory and point of care approach to intra-operative coagulation testing during cardiac surgery
  3. Identify the various methods of assessing heparin activity
  4. Assess the technological differences between different methods of measuring the Activated Clotting Time (ACT)
  5. Evaluate the clinical impact of the different ACT technologies

Continuing Education:
One P.A.C.E.® contact hour will be provided for this basic level session until December 4, 2018. Whitehat Communications is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program.
This session is approved for one Florida CE credit. Florida Board of Clinical Laboratory Personnel approved number: 50-12563

This event is produced by Whitehat Communications and sponsored by Abbott Point of Care.

   
 
 

PAMA IS HERE

PRESENTERS
RECORDING SLIDES

PAMA IS HERE:
NAVIGATING CHANGE AND ALIGNING
YOUR ORGANIZATION FOR SUCCESS


PRESENTERS


Charles Root, PhD | CEO, CodeMap LLC
Peter Kelly | Divisional VP, Abbott


SUMMARY

Representing the most significant clinical lab payment reform in over 30 years, the new Protecting Access to Medicare Act (PAMA) reimbursement rates became effective January 1, 2018.

Under PAMA, laboratory organizations will see a change in reimbursement paid for the highest volume lab tests under Medicare Part B. This includes Hospital Outpatient, Reference Labs, Independent Labs, Physician Offices, Ambulatory Surgery Centers, Long Term Cares, and all other outpatient facilities performing lab tests. In addition, Point of care testing will also experience different reimbursement rates due to the elimination of Automated Test Panels. With a heightened demand for financial discipline, labs will be empowered by a better understanding of their facility’s financial data, associated costs and payments, and overall strategy developed for sustainable business.

This webinar will describe the reimbursement environment leading to PAMA, identify PAMA payment impact for Medicare Part B (outpatient) lab services, discuss how the elimination of automated test panels (ATP) codes will affect reimbursement, and review how specific point of care assays are impacted by the new payment rates.
Learning objectives
  1. Describe the reimbursement environment leading to PAMA
  2. Identify PAMA payment impact for Medicare Part B (outpatient) lab services
  3. Discuss how the elimination of automated test panels (ATP) codes will affect reimbursement
  4. Review how specific point of care assays are impacted by the new payment rates


Continuing Education:

One P.A.C.E.® contact hour will be provided for this basic level session until September 21, 2018. Whitehat Communications is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program.
This session is approved for one Florida CE credit. Florida Board of Clinical Laboratory Personnel approved number: 50-12563

This event is produced by Whitehat Communications and sponsored by Abbott Point of Care.

   
 

TROPONIN ESSENTIALS

PRESENTER
RECORDING SLIDES

TROPONIN ESSENTIALS:
IMPLEMENTING THE GUIDELINES

PRESENTER
Ruth Cantu, BSN, RN, AACC
Program Manager, ACC Accreditation Services

Summary
The detection of a rise and/or fall of cardiac troponin plays a key role in identification of patients suspected of having an Acute Coronary Syndrome (ACS) and earlier diagnosis of myocardial infarction. However, individuals with non-ACS conditions can also have elevated cardiac troponin and many symptoms associated with non-ACS conditions may overlap with symptoms of ACS1. This presents a diagnostic challenge to the clinician and often requires an extended evaluation before the clinician can make an accurate diagnosis, which can impact efficiency and quality of care. This webinar will share an evidence-based approach to diagnosis and treatment of the ACS patient, with a focus on the current guidelines for troponin testing.
Learning objectives
  1. Identify guideline-driven best practice recommendations on the use of biomarkers in the treatment of Acute Coronary Syndrome (ACS)
  2. Review updates to the Myocardial Infarction (MI) Definition and Non-ST elevation Acute Coronary Syndromes (NSTE-ACS) guidelines
  3. Discuss troponin turn-around-time recommendations and documentation requirements
  4. Share quality practices that optimize the care and outcomes of ACS patients
Reference: 1. Third Universal Definition of Myocardial Infarction (MI), Kristian Thygesen, Joseph S. Alpert, Allan S. Jaffe, Maarten L. Simoons, Bernard R. Chaitman and Harvey D. White, Circulation 2012;126:2020-2035 
www.scpc.org/resources/PDFs/ThirdUniversalDefinitionofMyocardialInfarction_CIRC2012.pdf
Heart image w logos